{"entity":{"id":"nct07509008","kind":"trial","name":"Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum","aka":[],"tldr":"This study tests TROP-2-directed treatment; the registry reports that it is not yet recruiting.","summary":"The registry lists NCT07509008 as not yet recruiting, last updated 2026-07-29. Enrolment is 10 planned participants, an estimate. Interventions: TGFBR2 KO CAR27/IL-15 NK cells, Rimiducid (AP1903), Fludarabine, Cyclophosphamide. Primary measures include Safety and Adverse Events (AEs). No results are posted in the registry; this does not exclude separate publications.","status":"planned","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07509008","url":"https://clinicaltrials.gov/study/NCT07509008"}],"tags":[],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07509008","phase":"1/2","setting":"Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum","sponsor":"M.D. Anderson Cancer Center","started":"2026-09-01","startedType":"estimated","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07509008/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}]}}